Compare Stocks: QNRX, CRVO, CPHI, and ADXS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CPHI China Pharma	$0.90 +2.0%	$1.13	$0.38 ▼ $19.19	$38.90M	1.05	1.83 million shs	121,529 shs
CRVO CervoMed	$2.60 -1.5%	$3.00	$2.13 ▼ $10.89	$39.31M	-0.63	358,212 shs	264,442 shs
QNRX Quoin Pharmaceuticals	$6.12 +18.6%	$4.67	$3.25 ▼ $41.80	$12.29M	1.5	1.57 million shs	30.94 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,712.46%
CPHI China Pharma	0.00%	-7.74%	-30.45%	+15.61%	-35.42%
CRVO CervoMed	0.00%	-0.76%	+3.17%	-16.40%	-72.31%
QNRX Quoin Pharmaceuticals	0.00%	+9.87%	+39.09%	+20.95%	-18.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.60	$0.60	$0.00 ▼ $0.80	$35.79M	1.75	15,632 shs	N/A
CPHI China Pharma	$0.90 +2.0%	$1.13	$0.38 ▼ $19.19	$38.90M	1.05	1.83 million shs	121,529 shs
CRVO CervoMed	$2.60 -1.5%	$3.00	$2.13 ▼ $10.89	$39.31M	-0.63	358,212 shs	264,442 shs
QNRX Quoin Pharmaceuticals	$6.12 +18.6%	$4.67	$3.25 ▼ $41.80	$12.29M	1.5	1.57 million shs	30.94 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1,712.46%
CPHI China Pharma	0.00%	-7.74%	-30.45%	+15.61%	-35.42%
CRVO CervoMed	0.00%	-0.76%	+3.17%	-16.40%	-72.31%
QNRX Quoin Pharmaceuticals	0.00%	+9.87%	+39.09%	+20.95%	-18.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
CPHI China Pharma	0.00	N/A	N/A	N/A
CRVO CervoMed	2.71	Moderate Buy	$21.00	707.69% Upside
QNRX Quoin Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNRX, CRVO, CPHI, and ADXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/13/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/15/2026	QNRX Quoin Pharmaceuticals	ThinkEquity Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	11.05	N/A	N/A	($2.06) per share	-0.29
CPHI China Pharma	$3.91M	9.94	N/A	N/A	$0.70 per share	1.29
CRVO CervoMed	$4.01M	9.80	N/A	N/A	$1.97 per share	1.32
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$5.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	-$3.08M	-$0.43	N/A	N/A	N/A	-85.56%	-63.93%	-31.42%	N/A
CRVO CervoMed	-$26.97M	-$3.22	N/A	N/A	N/A	-672.80%	-156.02%	-128.34%	11/12/2026 (Estimated)
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)

Latest QNRX, CRVO, CPHI, and ADXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/7/2026	Q2 2026	CRVO CervoMed	-$0.8640	-$0.64	+$0.2240	-$0.64	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
CPHI China Pharma	0.22	0.79	0.26
CRVO CervoMed	N/A	8.57	8.57
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
CPHI China Pharma	N/A
CRVO CervoMed	25.15%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
CPHI China Pharma	6.40%
CRVO CervoMed	35.80%
QNRX Quoin Pharmaceuticals	11.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	59.31 million	42.36 million	Not Optionable
CPHI China Pharma	250	43.02 million	15.92 million	Not Optionable
CRVO CervoMed	4	15.12 million	9.71 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	2.01 million	1.78 million	Not Optionable

QNRX, CRVO, CPHI, and ADXS Headlines

Recent News About These Companies

Quoin Pharma raises up to $50M for rare disease development

August 29 at 6:47 PM | thepharmaletter.comT

Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement

August 28 at 1:38 PM | rttnews.com

Quoin Pharmaceuticals stock surges Friday: What's happening?

August 28 at 1:38 PM | msn.com

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

August 28 at 8:36 AM | rttnews.com

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

August 28 at 6:00 AM | globenewswire.com

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

August 28 at 6:00 AM | globenewswire.com

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

August 27 at 5:33 PM | finance.yahoo.com

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 14, 2026 | globenewswire.com

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on ...

August 7, 2026 | caledonianrecord.comC

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

August 7, 2026 | globenewswire.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

July 9, 2026 | finanznachrichten.de

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

July 9, 2026 | globenewswire.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

June 30, 2026 | finanznachrichten.de

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

June 30, 2026 | globenewswire.com

Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) - Share Price and Research

June 24, 2026 | intelligentinvestor.com.auI

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

June 23, 2026 | globenewswire.com

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

June 18, 2026 | globenewswire.com

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

June 16, 2026 | globenewswire.com

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

June 4, 2026 | globenewswire.com

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

June 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, CRVO, CPHI, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)

As of 08/28/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

China Pharma NYSE:CPHI

$0.90 +0.02 (+2.03%)

As of 08/28/2026 04:00 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

CervoMed NASDAQ:CRVO

$2.60 -0.04 (-1.52%)

As of 08/28/2026 04:00 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Quoin Pharmaceuticals NASDAQ:QNRX

$6.12 +0.96 (+18.60%)

As of 08/28/2026 04:00 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, CRVO, CPHI, and ADXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, CRVO, CPHI, and ADXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, CRVO, CPHI, and ADXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, CRVO, CPHI, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

China Pharma NYSE:CPHI

CervoMed NASDAQ:CRVO

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, CRVO, CPHI, and ADXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, CRVO, CPHI, and ADXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, CRVO, CPHI, and ADXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, CRVO, CPHI, and ADXS Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

China Pharma NYSE:CPHI

CervoMed NASDAQ:CRVO

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools